REG - GENinCode PLC - NHS LIPID inCode testing implementation

GenincodeAnnouncement

02/05/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230502:nRSB9734Xa&default-theme=true

RNS Number : 9734X  GENinCode PLC  02 May 2023

GENinCode Plc

("GENinCode" or the "Company")

 

NHS accelerates implementation of LIPID inCode® testing of patients

suffering with hypercholesterolemia and familial hypercholesterolemia

 

NHS earmarks budget to expand GENinCode's LIPID inCode® polygenic testing to
prevent Cardiovascular Disease

 

Oxford, UK. GENinCode Plc (AIM: GENI), the genetics company focused on the
prevention of cardiovascular disease, announces the expansion of its
collaboration with the Academic Health Science Network for the North East and
North Cumbria ("AHSN NENC") to use the LIPID inCode® polygenic test in
Primary Care for the diagnosis of familial (inherited) hypercholesterolemia
("FH") with available information to physicians for polygenic
hypercholesterolemia (high levels of cholesterol) and coronary heart disease
risk.

 

NHS funding to accelerate LIPID inCode® testing has been earmarked to improve
the diagnosis and treatment of FH to prevent cardiovascular disease ("CVD").
Expanding access to genetic testing for FH, which causes early onset of heart
attacks (myocardial infarction or "MI"), will enable the identification,
earlier diagnosis and treatment of patients at high genetic risk of a heart
attack. Improved detection of patients at genetic risk supports better
treatment and preventative care to avoid a heart attack. The acceleration of
LIPID inCode® testing will support the delivery of the NHS 10 Year Plan to
identify at least 25% of those individuals suffering with FH by 2024 as part
of the NHS genomics programme. The NHS 10 Year Plan for FH is at the forefront
of cardiovascular clinical improvements to reduce CVD mortality in the UK.
 

 

LIPID inCode® is the first commercial polygenic test to prevent CVD to be
implemented by the NHS. LIPID inCode® provides a comprehensive diagnosis of
FH and assesses an individuals inherited genetic risk of hypercholesterolemia
and coronary heart disease. GENinCode will deliver LIPID inCode® using its
proprietary SITAB 'cloud based' system and datasets enabling a rapid
turnaround of test results (10-15 days) at reduced cost to the NHS.

 

The NHS funding follows the positive results of the LIPID inCode® NHS
clinical study(1) and successful completion of the AHSN NENC pilot. The NHS
have now commenced LIPID inCode® testing in the Darlington Primary Care
Network (PCN) and community practice representing over 100,000 patients in the
North of England. The collaboration will diagnose patients with genetic
disorders giving rise to high levels of cholesterol an important risk factor
leading to the development of CVD.

 

In the UK around 7.6m people live with heart and circulatory disease, which
causes 25% of all deaths annually. CVD can be reduced by identifying and
treating individuals at risk, and the NHS 10 Year Plan (2019) sets out to
address CVD prevention, including identifying individuals with
hypercholesterolemia and particularly those with FH.  FH is an inherited
monogenic condition which affects an individual's ability to regulate and
remove cholesterol from their blood. FH affects approximately 1 in 250 people
in the UK population and globally.

 

Matthew Walls, CEO of GENinCode PLC said: "The collaboration with the AHSN
NENC continues to expand the use of LIPID inCode testing to identify patients
at high risk of heart disease representing the largest cause of death in the
UK and globally. We are now extending implementation of LIPID inCode to other
UK AHSN's marking a further NHS milestone for the roll-out and adoption of our
leading polygenic test. We look forward to supporting the NHS in reaching its
long term goal to diagnose patients with hypercholesterolemia and provide
earlier risk assessment of CVD to improve health outcomes."

 

Professor Julia Newton, Medical Director at AHSN NENC commented: "We are
delighted to accelerate the implementation of LIPID inCode® for the diagnosis
and treatment of hypercholesterolemia and familial hypercholesterolemia. The
added benefit of easy sample collection, improved test turnaround times at a
reduced costs to the NHS, continues to help us deliver the Lipid inCode test
in our primary care practice and we welcome this approach to help us deliver
the NHS 10-Year plan to reduce the onset of cardiovascular disease."

 

For more information visit www.genincode.com (http://www.genincode.com)

Enquiries:

 

 GENinCode Plc                          www.genincode.com (http://www.genincode.com) or via Walbrook PR
 Matthew Walls, CEO

 Stifel Nicolaus Europe Limited (Nomad and Joint Broker)                                      Tel: +44 (0)20 7710 7600
 Alex Price / Ben Maddison / Richard Short

 Cenkos Securities Plc (Joint Broker)   Tel: +44 (0)20 7397 8900
 Giles Balleny
 Dale Bellis / Michael Johnson (Sales)

 Walbrook PR Limited                                                Tel: 020 7933 8780 or genincode@walbrookpr.com

 Anna Dunphy / Phillip Marraige / Louis Ashe-Jepson

 

About GENinCode:

GENinCode Plc is a UK based company specialising in genetic risk assessment of
cardiovascular disease. Cardiovascular disease is the leading cause of death
and disability worldwide.

 

GENinCode operates business units in the UK, Europe through GENinCode S.L.U,
and in the United States through GENinCode U.S. Inc.

 

GENinCode predictive technology provides patients and physicians with globally
leading preventative care and treatment strategies. GENinCode CE marked
invitro-diagnostic molecular tests combine clinical algorithms and
bioinformatics to provide advanced patient risk assessment to predict disease
onset.

 

About Academic Health Science Network for the North East and North Cumbria
(AHSN NENC):

The AHSN NENC is focused on building and maintaining strong relationships and
partnerships which is fundamental to its success. Member organisations and
stakeholders include NHS, academia and industry partners in the North East and
North Cumbria.

By developing and maintaining strong relationships with members and
practitioners, the Network continually shares knowledge and translates ideas
into practice. The Network benefits from harnessing the expertise and
experience of clinical staff, for example, to act as change agents to adopt
and diffuse new practice across organisations and support the research
community to develop knowledge.

To deliver against what is a broad remit, the Network works in close
collaboration with The AHSN Network (http://www.ahsnnetwork.com/)  across
the UK as well as with other national organisations, such as NIHR Clinical
Research Network
(https://www.nihr.ac.uk/nihr-in-your-area/north-east-and-north-cumbria/) .
Other partnerships are developed where appropriate, for example, with the
third sector and with industry.

There are 15 Academic Health Science Networks ("AHSN") across England,
established by NHS England in 2013 to spread innovation at pace and scale -
thereby improving health and generating economic growth. Each AHSN works
across a distinct geography serving a different population in each region. The
AHSN NENC leads the national AHSN programme
(https://www.ahsnnetwork.com/about-academic-health-science-networks/national-programmes-priorities/lipid-management-and-fh)
to better identify FH in collaboration with the Accelerated Access
Collaborative (AAC) and the National Institute for Health & Care
Excellence (NICE).

 

 

About Cardiovascular Disease (CVD):

Heart and circulatory disease also known as Cardiovascular disease (CVD) is
the leading cause of death globally, taking an estimated 17.9 million lives
each year. CVD is a group of disorders of the heart and blood vessels that
include coronary heart disease, cerebrovascular disease, rheumatic heart
disease and other conditions. More than four out of five CVD deaths are due to
heart attacks and strokes, and one third of these deaths occur prematurely in
people under 70 years of age.

 

The most important behavioural risk factors of heart disease and stroke are
unhealthy diet, physical inactivity, tobacco use and harmful use of alcohol.
The effects of behavioural risk factors may show up in individuals as raised
blood pressure, raised blood glucose, raised blood lipids, and overweight and
obesity. These "intermediate risks factors" can be measured in primary care
facilities and indicate an increased risk of heart attack, stroke, heart
failure and other complications.

 

Identifying those at highest risk of CVDs and ensuring they receive
appropriate treatment can prevent premature deaths. Access to noncommunicable
disease medicines and basic health technologies in all primary health care
facilities is essential to ensure that those in need receive treatment and
counselling.

 

Cardiovascular disease, causes a quarter of all deaths in the UK and is the
largest cause of premature mortality in deprived areas and is the single
biggest area where the NHS can save lives over the next 10 years. CVD is
largely preventable, through lifestyle changes and a combination of public
health and NHS action on smoking and tobacco addiction, obesity, tackling
alcohol misuse and food reformulation.

 

Early detection and treatment of CVD can help patients live longer, healthier
lives is set out in the NHS 10 Year Plan. Too many people are still living
with undetected, high-risk conditions such as raised cholesterol, high blood
pressure and atrial fibrillation (AF). Globally, healthcare systems are making
progress on identification and diagnosis of high genetic risk individuals and
working towards people routinely knowing and understanding their 'ABC' (AF,
Blood pressure and Cholesterol risk). Replicating this approach is now
increasingly possible with advanced molecular testing and digital technology.

 

Expanding access to genetic testing for Familial Hypercholesterolemia (FH),
which causes early heart attacks will enable the diagnosis and treatment of
those patients at genetic risk of sudden cardiac death. The NHS set out in the
10 Year Plan to identify at least 25% of those individuals suffering with FH
by 2024 through the NHS genomics programme.

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCNKDBKKBKDNPK